AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03878667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curves Calcium
Description: Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
Study NCT02972736 — intervention group
Intervention type: RADIATION
Intervention: Radiation dose expressed as DAP
Study NCT03878667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curves Calcium
Description: Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
Study NCT03878667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium (providing 950 mg/d as carbonate)
Study NCT03878667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium (providing 950 mg/d as carbonate)
Study NCT03878667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose placebo
Study NCT03878667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose placebo
Study NCT01894776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
Study NCT01894776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
Study NCT02945852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib 500mg/d until progressive Disease
Study NCT01571167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
Study NCT01571167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
Study NCT01571167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
Study NCT00732472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 7 day repeat dose
Study NCT03557229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Oral: 50 mg once daily for 5 days
Study NCT03557229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 1 GM Oral Tablet
Description: Oral: 1 GM every 6 hours for 5 days
Study NCT03557229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 UNT
Description: Oral: 400 UNT every 8 hours for 5 days
Study NCT03557229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Oral: 1200 mg every 12 hours for 5 days
Study NCT04272814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression therapy
Description: Compression application
Study NCT04272814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: initial clinical assessment
Description: Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
Study NCT04272814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: initial clinical assessment
Description: Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
Study NCT02762760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMPION™
Description: AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
Study NCT03325283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProtEmbo Cerebral Protection System
Description: A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
Study NCT03042624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented rice
Description: 7 g of powder obtained from Lactobacillus paracasei CBA L74
Study NCT02762760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
Study NCT02029391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual pressure release
Description: Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
Study NCT02029391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual pressure release
Description: Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
Study NCT02029391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
Study NCT01755104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stablor
Study NCT01755104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02253394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan plus Spironolactone
Description: Cardiopulmonary fitness
Study NCT02253394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ambrisentan plus Placebo
Description: Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
Study NCT03042624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrins
Description: 7 g of maltodextrins powder
Study NCT03104829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Study NCT03104829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
Study NCT01611311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study NCT01611311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
Study NCT03296358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone
Description: The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
Study NCT02466204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corifollitropin alfa
Description: Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
Study NCT02466204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Beta
Description: Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
Study NCT03954184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx-TI with Product Training/On-line Support
Description: NIATx-TI framework includes the product training as well as a preimplementation phase and a post-implementation phase. A NIATx-TI coach will provide the training for this arm. The coach will also assist the organizations with applying the NIATx-TI framework.
Study NCT01386190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise/Social Behavioral
Description: Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
Study NCT01386190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise/Social Behavioral
Description: Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
Study NCT03099304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT03099304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT03099304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study NCT03099304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study NCT02117791 — intervention group
Intervention type: DRUG
Intervention: Riociguat (ADEMPAS, BAY63-2521)
Description: The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
Study NCT01264692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-280778
Description: 10 mg once daily for 28 ± 2 days
Study NCT01264692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules matching ACT-280778
Study NCT01264692 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: 10 mg once daily for 28 ± 2 days
Study NCT03296358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Description: The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
Study NCT04668625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participate in a massive musical event
Description: Participate in a massive musical event
Study NCT02232165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypotension avoidance
Description: Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP >= 65 mmHg is not inferior to induced hypertension.
Study NCT02232165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced hypertension
Description: Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
Study NCT02407353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
Study NCT02407353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo which will be dosed as oral suspension, single doses to match PF-06648671
Study NCT02277756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermode
Description: thermal stimulation with test thermode
Study NCT02277756 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: thermode
Description: thermal stimulation with test thermode
Study NCT00848874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PVGS
Description: Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
Study NCT02294591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Add-on treatment of NAC
Study NCT03520894 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: single 21 Gy fraction of Radiotherapy before surgery
Study NCT03336203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
Description: treatment either with allopurinol or febuxostat
Study NCT02237898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoMba Live Long app & Sensordrone™ carbon-monoxide sensor
Description: MoMba Live Long application \& Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
Study NCT02237898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office contingency management
Description: A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
Study NCT02237898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensordrone™ carbon-monoxide sensor
Description: A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
Study NCT02237898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensordrone™ carbon-monoxide sensor
Description: A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
Study NCT02237898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoMba Live Long Smartphone application
Description: The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
Study NCT01456728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Progastria
Description: All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days.
Study NCT01456728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
Study NCT01627041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01627041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT01627041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT01627041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04168164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic therapy
Description: The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
Study NCT01627041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03876704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of fat-Soluble Vitamin
Description: Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
Study NCT03876704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dose of fat-Soluble Vitamin
Description: Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
Study NCT02294591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Add-on treatment of placebo
Study NCT03923712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Programme
Description: The methodology will be multicomponent, including aerobic, strength, coordination-cognitive and balance-agility. The physical exercise sessions will be designed in such a way that they work the dimensions but being attractive and motivating for the participants. Each session will include 10 minutes of warm-up with smooth running and mobility exercises; 35-40 minutes of aerobic, strength, coordination-cognitive and balance-agility progressively developed; and 10 minutes back to calm at low intensity with stretching exercises. Nutritional intervention will not be included. For quality purposes, we will use small groups (10-15 pers). After each session participants will be asked about their subjective perception of the effort and the intensity will be controlled by heart rate monitors.
Study NCT04168164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry land therapy
Description: sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
Study NCT04168164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined therapy
Description: alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
Study NCT03610516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Multiple doses of 10 mg/kg CFZ533 intravenous (IV) infusion. CFZ533 was administered every 4 weeks (Q4W; from Day 1 to Day 141), plus an additional dose of 10 mg/kg IV at Day 15, resulting in a Q2W loading regimen up to the third dose on Day 29.
Study NCT02855086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously (IV)
Study NCT02855086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye 800CW
Description: Administered intravenously (IV)
Study NCT02855086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor resection
Description: Standard of care treatment
Study NCT02817100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
Study NCT03610516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multiple doses of placebo intravenous infusion
Study NCT02031510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: transversus abdominis plane block with saline 0.9%
Study NCT02031510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: transversus abdominis plane block bupivacaine 0.25%